Introduction
============

Cervical cancer is the fourth leading cause of cancer death among women worldwide. The main treatments consist of radiation therapy, surgery, chemotherapy, or a combination of these options. In advanced stages (IIB--IVA), radiation therapy concurrent with chemotherapy (ie, chemoradiation or chemoradiotherapy) is standard, and platinum-based chemotherapy protocols are preferable. According to the National Cancer Institute, the benefit of concurrent cisplatin-based chemoradiation in women with cervical cancer exceeds that of radiotherapy alone.[@b1-ott-6-297]

However, in patients receiving adjuvant chemoradiotherapy, hematologic and gastrointestinal toxicities are risk factors for reduced adherence to the regimen,[@b2-ott-6-297] as some patients cannot tolerate all courses.[@b3-ott-6-297] It must be recognized that both the disease broad ligament where the uterine and the effects of treatment compromise in many ways the wellbeing and quality of life of these women. Although the most common regimens are a combination of 5-fluorouracil (5-FU) and cisplatin administered at three to 4-week intervals, the optimal dose and dosage have not been determined.[@b3-ott-6-297]--[@b6-ott-6-297]

We conducted the present retrospective study to evaluate the efficacy of incomplete treatment in chemoradiation with 5-FU and cisplatin for locally advanced cervical carcinoma. Our primary goal was to compare treatment outcomes, including survival and recurrence rates, in an effort to determine the superior chemoradiotherapy regimen. We also evaluated patients' ability to adhere to the planned regimen and associated toxicities.

Materials and methods
=====================

Patients
--------

The Ethics Committee of the First Affiliated Hospital of Medical College of Xi'an Jiaotong University approved this study. Data were collected retrospectively from the records of 156 consecutive patients with locally advanced cervical cancer who had been treated with combined radiotherapy and chemotherapy from October 2006 to October 2008. All patients had provided written informed consent for treatment.

The patients included in this study presented with International Federation of Gynecology and Obstetrics stages IIB--IIIB (IIB: cervical carcinoma invades beyond the uterus with obvious parametrial invasion, but not to the pelvic wall or to the lower third of the vagina; IIIB: tumor extends to the pelvic wall, involves the lower third of the vagina and/or causes hydronephrosis or non-functioning kidney), good performance status (Eastern Cooperative Oncology Group score of 0 \[asymptomatic\], or 1 \[symptomatic but ambulatory\]), no uncontrolled concomitant disease, no connective tissue disease, and no prior irradiation. For evaluation, the patients were assigned to either of two groups. Patients in group I completed two cycles of the chemotherapy regimen, and those in group II received fewer than two cycles.

Radiation therapy
-----------------

External beam radiation therapy was delivered in a conventional fraction (1.8 Gy/fraction, 5 fractions/week) using a 10-MV photon beam from a linear accelerator. A total dose of 50.4 Gy was administered to the entire pelvis. This was followed by intracavitary brachytherapy at a dose of 5 Gy in 4 fractions to point A (the paracervical triangle in the medial edge of the broad ligament where the uterine vessels cross the ureter) which was delivered by a remote afterloading system. External beam radiation therapy was interrupted if the white blood cell count fell below 1000/mm^3^ or if platelets fell below 50,000/mm^3^, and was resumed once counts rose above these levels.

Chemotherapy
------------

Cisplatin and 5-FU were the chemotherapy agents administered. Cisplatin was given in a dose 40 mg m^−2^ d^−1^ for 3 days; 5-FU was given at 500 mg m^−2^ d^−1^ continuous infusion from the first to the fifth day with radiotherapy. A 3-week rest separated the two cycles.

Patients were seen weekly by a physician for a physical examination and a complete blood count test. Chemotherapy was stopped if creatinine clearance was \<30 mL/min, and interrupted if patients had ≥grade 3 gastrointestinal toxicity, the total white blood cell count was ≤4000/mm^3^, or platelets were ≤100,000/mm^3^. Granulocyte colony-stimulating factors were used when absolute neutrophil count fell ≤ 500/mm^3^ or total white blood cell count fell ≤1000/mm^3^.

Toxicity
--------

During treatment, toxicities were assessed weekly and graded in accordance with the National Cancer Institute Common Terminology Criteria of Adverse Events (version 3.0): 1, mild; 2, moderate; 3, severe; and 4, life-threatening or disabling.[@b7-ott-6-297]

Statistical analyses
--------------------

Data were stored and analyzed using SPSS version 17.0 software (IBM Corporation, Armonk, NY, USA). The Kaplan-Meier approach and the log-rank test were used to compare survival profiles between the two patient groups. *P* \< 0.05 was considered significant for all statistical analyses.

Results
=======

Patient characteristics
-----------------------

The median age of the patients in groups I and II at the time of diagnosis was 50 and 51 years, respectively. In total, 156 patients were included from October 2006 to October 2008 ([Table 1](#t1-ott-6-297){ref-type="table"}). One hundred and one (64.7%) patients were diagnosed as International Federation of Gynecology and Obstetrics stage IIB, and 55 (35.3%) in stage IIIB. One hundred and sixteen patients had squamous cell carcinoma (74.4%) and 37 (23.7%) had adenocarcinoma. The histology of the remaining three patients (1.9%) is unknown.

Eighty-nine patients (57%, group I) completed the two cycles of cisplatin (40 mg/m^2^) and 5-FU (500 mg/m^2^), while 67 patients (43%, group II) received fewer than two cycles. The most common causes for not completing the chemotherapy plan were neutropenia (95.6%), anemia plus neutropenia (57.8%), and others (1.3%).

Survival and local control
--------------------------

With a median follow-up time of 37.5 months (range 7--65 months), the local control for groups I (completed two cycles) and II (completed \<2 cycles) were 92.1% and 80.6%, respectively ([Table 2](#t2-ott-6-297){ref-type="table"} and [Figure 1](#f1-ott-6-297){ref-type="fig"}). Disease-free survival for the two groups was 80.9% and 73.2%, overall survival was 84.3% and 79.1%, and progression survival was 3.4% and 3.0%. As shown by univariate analyses, only in local control was there a statistically significant difference between the two groups (*P* = 0.033).

Considering only stage IIB patients in the treatment groups, local control was achieved by 96.8% in group I and 86.8% in group II, while disease-free survival was 85.7% and 78.9%, respectively, and overall survival rates were 88.9% and 84.2% ([Table 2](#t2-ott-6-297){ref-type="table"} and [Figure 1](#f1-ott-6-297){ref-type="fig"}). For stage IIIB patients, local control was achieved by 80.8% and 72.4% in groups I and II, respectively, while disease-free survival was 69.2% and 65.5%, and overall survival rates were 73.0% and 72.4%, respectively.

Toxicities
----------

Grade 3--4 anemia and neutropenia was found in 11 and 20 patients, respectively ([Table 3](#t3-ott-6-297){ref-type="table"}). In group I, three and six patients developed grade 3--4 anemia and neutropenia, respectively, while in group II, 8 and 14 patients developed these side effects, respectively. The differences in acute grade 3--4 hematologic toxicity between the two patient groups was significant (*P* = 0.038 for anemia; *P* = 0.009 neutropenia). Fifteen patients developed grade 1--2 thrombocytopenia.

There was no statistical difference between the patient groups in terms of the incidence of grade 1--2 subcutaneous toxicity ([Table 4](#t4-ott-6-297){ref-type="table"}). However, while none of the patients in group I developed grade 3--4 subcutaneous toxicity, in group II 8 of 67 (11.9%) developed this condition (*P* = 0.001).

Discussion
==========

Based on five large randomized trials in which 30% to 50% improvements in survival rates were shown, cisplatin-based chemoradiotherapy has become the standard treatment for women with locally advanced cervical cancer.[@b8-ott-6-297]--[@b12-ott-6-297] In addition, for these women chemoradiotherapy with concurrent cisplatin and 5-FU had several survival advantages over extended field radiation alone or oral administration of hydroxyurea.[@b9-ott-6-297],[@b12-ott-6-297]

The most popularly applied chemotherapeutic regimens are weekly cisplatin or combined cisplatin and 5-FU at three to 4-week intervals, but the optimal dose and dosage have not yet been definitively determined because of the toxicities associated with these agents. In GOG-120, GOG-165, and other similar clinical trials, only 50% to 70% of patients were able to complete six cycles of cisplatin as scheduled without dose decreases or interval changes.[@b13-ott-6-297],[@b14-ott-6-297] In addition, a study by Ryu et al[@b15-ott-6-297] found that triweekly cisplatin-based radiochemotherapy had more survival benefit and less associated neutropenia than a weekly treatment for locally advanced cervical cancer. Yet the association between completion of scheduled treatment and prognosis has not been investigated as thoroughly, although a series of literature reports have revealed a reduced adherence rate for chemoradiation with cisplatin.

The Some trial found that chemotherapy with 5-FU and cisplatin when added to external beam and intracavitary radiation significantly improved survival in locally advanced cervical cancer.[@b16-ott-6-297] The addition of 5-FU was based on the fact that this agent and its metabolites inhibit angiogenesis induced by vascular endothelial growth factor, and thus has an antitumor effect on cervical and colon cancers.[@b17-ott-6-297],[@b18-ott-6-297] A statistically significant benefit was also shown for adjuvant pelvic radiation concurrent with 5-FU and cisplatin in the treatment of patients with high risk factors found at surgery.[@b1-ott-6-297] In addition, preoperative chemoradiotherapy with cisplatin and 5-FU improves the survival of patients with locally advanced adenocarcinoma of the cervix, with manageable toxicities.[@b19-ott-6-297] However, little has been reported on the effect of non-adherence to scheduled treatment of chemoradiotherapy with cisplatin and 5-FU every 3 weeks in locally advanced cervical cancer.

In the present study, only 57% of patients completed the planned protocol of two cycles of cisplatin and 5-FU, and we found that in terms of local control with a median 37.5-month follow-up less than two cycles was not as effective (92.1% for those completing the regimen, compared to 80.6% of those who did not; *P* = 0.033). However there were no statistically significant differences in disease free survival or overall survival between the two groups. Patients at stage IIB who did not complete the two planned cycles were also able to achieve 3-year local control, disease free survival, and metastasis free survival that was comparable to those who completed the regimen. For patients in stage IIIB, there was also no statistical difference in 3-year local control, disease free survival, or overall survival between those who adhered to the regimen and those who could not.

We also found that compliance with treatment and acute hematologic toxicity were similar with the single chemotherapy agents with weekly cisplatin.[@b6-ott-6-297],[@b12-ott-6-297]--[@b14-ott-6-297] In contrast, Kim et al[@b20-ott-6-297] reported that, compared to a monthly cisplatin plus 5-FU regimen, patients adhered more successfully to weekly cisplatin, which reduced acute hematologic toxicity and had no effect on response and survival rates. According to the results of several studies, treatment outcomes for cisplatin alone and the cisplatin plus 5-FU regimen are similar, but there are considerable differences in acute toxicity and compliance.[@b14-ott-6-297] We found no occurrence of nephrotoxicity in the present study. However, in a study of 165 patients treated with cisplatin and chemoradiation, Tharavichitkul et al[@b6-ott-6-297] reported nephrotoxicity in 14 patients, and three patients developed grade 3--4 toxicity.

In our study, completion of two cycles of 5-FU/cisplatin and radiotherapy significantly improved local control, when considering the entire patient group. Those patients who did not complete treatment had significantly more anemia and neutropenia, and these side effects were, in general, the cause of non-compliance. Further investigation of patients' inability to complete scheduled chemoradiation revealed that adverse side effects, patient motivation, and laboratory profiles all contributed to lack of success. We recommend that for locally advanced cervical cancer, clinicians consider cytokine and blood product support to improve patient compliance with chemotherapy, and that total treatment time should be kept to the minimum required to optimize therapy. These findings are in accord with the literature as well.

Our results are limited by the study's retrospective design and because data was obtained from a single institution. The sample size is probably insufficient for subgroup calculations, although the completed chemoradiotherapy regimen showed a marked advantage in local control. The sample size of the study was determined by local patient volume, and we cannot exclude the possibility that other factors such as tumor size might be significant correlates of survival. We believe that by adjusting treatment for tumor size, we compensated to some extent for its adverse prognostic import. Yet the findings of this study confirm our clinical impressions and provide important information with which to move forward in developing better therapies for locally advanced cervical cancer.

Conclusion
==========

In conclusion, we found that chemoradiotherapy with 5-FU and cisplatin was associated with tolerable acute and long-term toxicity, and is safe and effective. In women with locally advanced cervical cancer, completed chemoradiotherapy with two cycles of cisplatin and 5-FU improved local control over incomplete treatment. No differences were found in disease free and overall survival. The present study supports the significant need for patients to adhere to chemoradiation therapy.
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###### 

Clinicopathology of patients by treatment group

                                               Group I[a](#tfn1-ott-6-297){ref-type="table-fn"}   Group II[b](#tfn2-ott-6-297){ref-type="table-fn"}   *P*-value
  -------------------------------------------- -------------------------------------------------- --------------------------------------------------- -----------
  Age (mean year, range)                       50, 31--68                                         51, 33--69                                          0.96
  Duration of treatment (median days, range)   49, 42--62                                         50, 43--65                                          0.89
  FIGO stage (n, %)                                                                                                                                   
   IIB                                         63, 70.1                                           38, 56.7                                            0.069
   IIIB                                        26, 29.9                                           29, 43.3                                            
  Histology (n, %)                                                                                                                                    
   Squamous cell carcinoma                     61, 68.5                                           55, 82.1                                            0.158
   Adenocarcinoma                              26, 29.2                                           11, 16.4                                            
   Unknown                                     2, 2.3                                             1, 1.5                                              

**Notes:**

Two cycles, n = 89;

fewer than two cycles, n = 67.

**Abbreviation:** FIGO, international Federation of Gynecology and Obstetrics.

###### 

Three-year local control, disease free survival, and overall survival rates stratified by patient group

                                Group I[a](#tfn4-ott-6-297){ref-type="table-fn"} (n, %)   Group II[b](#tfn5-ott-6-297){ref-type="table-fn"} (n, %)   *P*-value
  ----------------------------- --------------------------------------------------------- ---------------------------------------------------------- -----------
  Local control rates           82, 92.1                                                  54, 80.6                                                   0.033
   Stage IIB                    61, 96.8                                                  33, 86.8                                                   0.130
   Stage IIIB                   21, 80.8                                                  21, 72.4                                                   0.467
  Disease free survival rates   72, 80.9                                                  49, 73.2                                                   0.250
   Stage IIB                    54, 85.7                                                  30, 78.9                                                   0.581
   Stage IIIB                   18, 69.2                                                  19, 65.5                                                   0.769
  Overall survival              75, 84.3                                                  53, 79.1                                                   0.405
   Stage IIB                    56, 88.9                                                  32, 84.2                                                   0.496
   Stage IIIB                   19, 73.0                                                  21, 72.4                                                   0.956
  Progression survival          3, 3.4                                                    2, 3.0                                                     0.892

**Notes:**

Two cycles, n = 89;

fewer than two cycles, n = 67.

###### 

Acute toxicities stratified by patient group

                     Group I[a](#tfn6-ott-6-297){ref-type="table-fn"} (n, %)   Group II[b](#tfn7-ott-6-297){ref-type="table-fn"} (n, %)   *P*-value
  ------------------ --------------------------------------------------------- ---------------------------------------------------------- -----------
  Anemia                                                                                                                                  
   Grade 1--2        48, 53.9                                                  44, 65.7                                                   0.140
   Grade 3--4        3, 3.4                                                    8, 11.9                                                    0.038
  Neutropenia                                                                                                                             
   Grade 1--2        74, 83.1                                                  50, 74.6                                                   0.192
   Grade 3--4        6, 6.7                                                    14, 20.9                                                   0.009
  Thrombocytopenia                                                                                                                        
   Grade 1--2        7, 7.9                                                    8, 11.9                                                    0.393

**Notes:**

Two cycles, n = 89;

fewer than two cycles, n = 67.

###### 

Toxicities stratified by patient group (n, %)

                        Group I[a](#tfn8-ott-6-297){ref-type="table-fn"} n   Group II[b](#tfn9-ott-6-297){ref-type="table-fn"} n   *P*-value
  --------------------- ---------------------------------------------------- ----------------------------------------------------- -----------
  Subcutaneous tissue                                                                                                              
   Grade 1--2           23, 25.8                                             18, 26.9                                              0.886
   Grade 3--4           0, 0                                                 8, 11.9                                               0.001
  Gastrointestinal                                                                                                                 
   Grade 1--2           7, 7.9                                               4, 6.0                                                0.647
   Grade 3--4           0, 0                                                 2, 3.0                                                0.101
  Genitourinary                                                                                                                    
   Grade 1--2           7, 7.9                                               5, 7.5                                                0.926
   Grade 3--4           0, 0                                                 1, 1.5                                                0.248

**Notes:**

Two cycles, n = 89

fewer than two cycles, n = 67.
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